Fig. 5 | Leukemia

Fig. 5

From: Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma

Fig. 5

The durability of JAK3 inhibition in vitro and in vivo, and the efficacy of PRN371 in vivo. Wash-out experiment of NK-S1 a and KAI-3 b cells treated with 1.0 µM of PRN371 or tofacitinib for 2 h and harvested at different time points as indicated. DMSO treatment served as control. c Immunoblots of JAK3-STAT signaling activity in Nod/Scid mice bearing NK-S1 tumors treated with vehicle or 25 or 50 mg/kg of PRN371. The tumors were harvested at indicated time points after the treatment. d Mice bearing NK-S1 tumors were treated with the indicated concentrations of PRN371 for 14 days. Tumor growth is presented as mean ± s.d.

Back to article page